Current Research
The types of research currently undertaken at the Trust are varied, from complex clinical trials, qualitative health service research, registries, post-marketing surveillance to trainee doctors and students doing low risk, own account studies. Much of this research has been adopted by the National Institute of Health Research, with a small number of commercial/pharmaceutical research making up the rest.
Cancer Research
Breast
ATNEC: A randomised trial investigating the requirement for axillary treatment, after chemotherapy, for patients with early stage breast cancer.
Principal Investigator (PI): Ms Werbena Hamilton-Burke
Colorectal
Yorkshire Cancer Research Bowel Cancer Improvement Program: Does intensive multidisciplinary team intervention improve bowel cancer outcomes in Yorkshire.
Principal Investigator (PI): Ms Paula Pickersgill
OnCoRe: Oncological Outcomes after Clinical Complete Response (cCR) in patients with rectal cancer.
Principal Investigator (PI): Miss Tamsyn Grey
FOxTROT2: Personalising neo-adjuvant Chemotherapy in Locally advanced but operable colon cancer. A randomised trial programme.
Principal Investigator (PI): Dr Sam Turnbull
FOxTROT3: A phase III randomized trial evaluating neoadjuvant chemotherapy with mFOLFOXIRI compared with neoadjuvant OxFp in patients with locally advanced but operable colon cancer
Principal Investigator (PI): Dr Sam Turnbull
ARIEL: A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tumour location (right-PTL).
Principal Investigator (PI): Dr Sam Turnbull
TRACC-C: Tracking mutations in cell free tumour DNA to predict relapse in early colorectal cancer.
Principal Investigator (PI): Dr Sam Turnbull
Haematology
CML Registry: The study programme to investigate modern trends in Chronic Myeloid Leukemia (CML).
Principal Investigator (PI): Dr Kate Rothwell
EUMDS: A prospective, multicentre European Registry for newly diagnosed patients with Myelodysplastic Syndromes of IPSS low and intermediate-1 subtypes
Principal Investigator (PI): Dr Kate Rothwell
RADAR (UK-MRA Myeloma XV): Risk-Adapted therapy Directed According to Response comparing treatment escalation and de-escalation strategies in newly diagnosed patients with multiple myeloma (NDMM) suitable for stem cell transplant (TE).
Principal Investigator (PI): Dr Sylvia Feyler
BGB-3111-308: A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB 3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma.
Prinicipal Investigator (PI): Dr Sylvia Feyler
COSMOS: Characterising risk and biology Of Smouldering Myeloma for early detection Of Symptomatic myeloma.
Prinicipal Investigator (PI): Dr Sylvia Feyler
Lung
REFINE-LUNG: A randomised open-label phase III trial of Reduced Frequency pembrolizumab immuNothErapy for first line treatment of patients with advanced non-small cell lung cancer (NSCLC) utilising a novel multi-arm frequency-response optimisation design.
Principal Investigator (PI): Dr Emma Rathbone
SUNRAY-01: A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing FirstLine Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression.
Principal Investigator (PI): Dr Emma Rathbone
SUNRAY-02: A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants with Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer.
Principal Investigator (PI): Dr Emma Rathbone
Pancreatic
UK-EDI: UK Early Detection Initiative for Pancreatic Cancer.
Principal Investigator (PI): Dr Sabari Haridass
Urology
BC-RECON: Diagnosing Bladder Cancer- evaluating the role of a urinary biomarker test in the Reconfiguration of the haematuria clinic investigations.
Principal Investigator (PI): Mr Tahir Qayyum
ORION-BC: A phase III, single-arm study to evaluate the efficacy and safety of ONCOFID-P-B (paclitaxel-hyaluronic acid conjugate) administered intravesically to patients with BCGunresponsive Carcinoma in Situ of the bladder with or without Ta-T1 papillary disease.
Principal Investigator (PI): Mr Tahir Qayyum
Other
ICI Genetics: Identification of genetic factors that predispose to immune checkpoint inhibitor toxicity. Participants recruited from all forms of cancer.
Principal Investigator (PI): Dr Emma Rathbone
APPROACH: An app for health & wellbeing after cancer – a randomised controlled trial.
Prinicipal Investigator (PI): Nicky Hill
Other Specialty Research
Cardiovasular
EASY-AS: A Randomised Controlled Trial of Early valve replacement in severe ASYmptomatic Aortic Stenosis.
Principal Investigator (PI): Dr Hossam Elmahy
AMEND-CRT: Assessment of Mechanical Dyssynchrony as Selection Criterion for Cardiac Resynchronisation Therapy.
Principal Investigator (PI): Dr Hossam Elmahy
EASi-HF: A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) ≥40%.
Principal Investigator (PI): Dr Azeem Sheikh
CHART: Comprehensive geriatric assessment (CGA) to sustain independence for older people living with heart failure with preserved ejection fraction (HFpEF) and frailty.
Principal Investigator (PI): Dr Hossam Elmahy
Critical Care
SIGNET: Statins for Improving Organ Outcome in Transplantation.
Principal Investigator (PI): Dr Paul Knight
MOSAICC: Evaluating the clinical and cost-effectiveness of Sodium Bicarbonate administration for critically ill patients with Acute Kidney Injury and metabolic acidosis.
Principal Investigator (PI): Dr Aaron Corp
Dermatology
BADBIR: British Association of Dermatologists Biologics and Immunomodulators Register
Principal Investigator (PI): Tracy Tatchell-Adams
Diabetes & Endocrinology
PROTECT: PRegnancy Outcomes using continuous glucose monitoring TEChnology in pregnant women with early-onset Type 2 diabetes.
Principal Investigator (PI): Dr Julie Kway-Tun
Frequency of Ketosis in People Living with Diabetes or Other Medical Conditions
Principal Investigator (PI): Dr Rob Moisey
IMVT-1402-2502: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease.
Principal Investigator (PI): Dr Rob Moisey
Emergency Care
CRASH-4: Intramuscular tranexamic acid for the treatment of symptomatic mild traumatic brain injury in older adults: a randomised, double-blind, placebo-controlled trial.
Principal Investigator (PI): Dr Huw Masson
ENT
STARFISH: A randomised controlled trial of STeroid Administration Routes For Idiopathic Sudden sensorineural Hearing loss.
Principal Investigator (PI): Dr George Elmaraghi
Gastroenterology
IBD BioResource: The UK Inflammatory Bowel Disease Bioresource: Progressing from Genetics to Function and Clinical Translation in Crohn's Disease & Ulcerative Colitis.
Principal Investigator (PI): Dr Sunil Sonwalker
GONDOMAR: Goals, Needs and outcome Determinants Of Multimodal therapy in Perianal Crohn's fistula.
Principal Investigator (PI): Dr Mohammed Allah-Ditta
ABX464-105: A randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of ABX464 once daily for induction treatment in subjects with moderately to severely active ulcerative colitis.
Principal Investigator (PI): Dr Mohamed Yousif
MK7240-001: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of MK-7240 in Participants with Moderately to Severely Active Ulcerative Colitis.
Principal Investigator (PI): Dr Mohamed Yousif
MK7240-008: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to
Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely
Active Crohn’s Disease.
Principal Investigator (PI): Dr Mohamed Yousif
Haematology
MDS Registry for newly diagnosed patients: A prospective, multicentre European Registry for newly diagnosed patients with Myelodysplastic Syndromes of IPSS low and intermediate-1 subtypes
Principal Investigator (PI): Dr Kate Rothwell
Hepatology
PBC Genetics Study: Investigation of the Genetic and Molecular Pathogenesis of Primary Biliary Cirrhosis.
rincipal Investigator (PI): Dr Susan Jones
Infection
DURATION-UTI: Impact of duration of antibiotic treatment on symptoms, recovery and antibiotic resistance in adult women with urinary tract infections (UTIs): a randomised controlled trial.
Principal Investigator (PI): Dr Rangaprasad Karadi
TILIA: A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen.
Principal Investigator (PI): Dr Yaqoob Ghumro
Musculoskeletal
BSRBR: Toxicity from biologic therapy
Principal Investigator (PI): Dr Omer Sharif
Obstetric & Gynaecology
TTTS Registry: A physician-run Multiple Pregnancy Registry in collaboration with the Twin & Multiple Births Association (TAMBA), designed to serve the interests of patients while overcoming challenges of sharing data over great distances while protecting patient privacy.
Principal Investigator (PI): Dr Fifydani Shamsudin
CAPE: Calcium Supplementation for Prevention of Pre-eclampsia in High Risk Women.
Principal Investigator (PI): Dr Fifydani Shamsudin
MINESS 20-28: Mothers Working to Prevent Early Stillbirth Study 20-28.
Principal Investigator (PI): Rebecca Leon
OBS UK: Clinical and cost-effectiveness of a maternity quality improvement programme to reduce excess bleeding and need for transfusion after childbirth.
Principal Investigator (PI): Mohamed Wahby
FEEL-GOOD: Female Empowerment through Enhanced Living: a comparison of vaGinal continence devices and pelvic flOOr muscle training (PFMT) versus PFMT only for female stress urinary incontinence: a feasibility and pilot StuDy. Stage 2
Principal Investigator (PI): Miss Yi Ling Chan
Paediatric
Cleft Collective: Cohort Studies - a large DNA backed prospective resource for the study of the genetic and environmental determinants of cleft lip and/or palate and the long term outcomes in children with cleft lip and/or palate.
Principal Investigator (PI): Rebecca Leon
FEED1 - Fluids Exclusively Enteral from Day 1: A randomised controlled trial of full milk feeds versus intravenous fluids with gradual feeding for preterm infants (30-33 weeks gestational age).
Principal Investigator (PI): Dr Abdul Mattara
WHEAT: WithHolding Enteral Feeds Around Blood Transfusion – the WHEAT International Trial.
Principal Investigator (PI): Dr James Houston
MAPS: Mental Health Admissions to Paediatric Wards Study - WP2 & WP3.
Principal Investigator (PI): Angie Salmons
SPIROMAC: SPIROmetry to Manage Asthma in Children.
Principal Investigator (PI): Dr James Houston
NeoGASTRIC: Avoiding routine gastric residual volume measurement in neonatal critical care: a multi-centre randomised controlled trial.
Principal Investigator (PI): Dr Karin Schwarz
Physiotherapy
RaCeR 2: Clinical and cost-effectiveness of individualised (early) patient-directed rehabilitation versus standard rehabilitation after surgical repair of the rotator cuff of the shoulder: a multi-centre, randomised controlled trial with integrated Quintet Recruitment Intervention.
Principal Investigator (PI): Tash Maher
Renal & Urogenital
RADAR: National Studies of Rare Kidney Diseases
Principal Investigator (PI): Dr Rahul Vundru
Respiratory
ASPECT: Aspirin after hospitalisation with pneumonia to prevent cardiovascular events randomised controlled trial.
Principal Investigator (PI): Dr Purav Desai
SENSOR: Physiological and environmental data in a remote setting to predict exacerbation events in patients with chronic obstructive pulmonary disease: an observational study
Principal Investigator (PI): Dr Andrew Hardy
EMBARK: A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease.
Principal Investigator (PI): Dr Andrew Hardy
Stroke
MAPS-2: Metoclopramide for Avoiding Pneumonia after Stroke (MAPS-2) Trial.
Principal Investigator (PI): Dr Syed Ahmad
LIBREXIA STROKE: A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack.
Principal Investigator (PI): Dr Tariq Salman
Surgical
MEErKAT: Mesenteric Excision and Kono-S Anastomosis Trial
Principal Investigator (PI): Mr Simon Gonsalves
E-BRIC: Early bowel resection for terminal ileal Crohn’s disease: exploring patients’ and clinicians’ perspectives and barriers to implementation.
Principal Investigator (PI): Miss Tamsyn Grey
RESPOND study (Rescue for Emergency Surgery Patients Observed to uNdergo acute Deterioration) Work Package 4: A cluster-randomised stepped-wedge Trial of a complex Human Factors intervention.
Principal Investigator (PI): Mr Arin Saha
OCEAN: Optimisation before Crohn’s surgery using Exclusive Enteral Nutrition.
Principal Investigator (PI): Mr Muneer Junejo
Trauma & Orthopaedics
DIDACT: Surgery compared with sling immobilisation in the management of adults with a
displaced fracture of the distal clavicle: a multi-centre, pragmatic, parallel group,
non-inferiority, randomised controlled trial.
Principal Investigator (PI): Mr Neil Pennington
REPPORT: REcurrent Patellar dislocation: Personalised therapy or OpeRative Treatment?
Principal Investigator (PI): Mr Osman Riaz
Studies In Follow-Up
Accident & Emergency
HUSH:The Humeral Shaft Fracture Trial: A multi-centre Prospective Randomised Superiority Trial of Surgical Versus Non-Surgical Interventions for Humeral Shaft Fractures in Patients Aged 18 Years or Older.
Principal Investigator (PI):Mr Simon Fogerty
Cancer
Add-Aspirin: A phase III double-blind placebo-controlled randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours.
Principal Investigator (PI): Dr Jo Dent
FAST-Forward: To Identify A 5-Fraction Schedule Of Curative Radiotherapy Delivered In 1 Week That Is At Least As Effective And Safe As The Current UK Standard 15-Fraction Regimen Delivered Over 3 Weeks Following Primary Surgery For Early Breast Cancer.
Principal Investigator (PI): Mr Neil Roberts
FLAIR: Front-Line therapy in CLL: Assessment of Ibrutinib + Rituximab, A phase III, multicentre, randomised, controlled, open, parallel group trial in patients with previously untreated CLL.
Principal Investigator (PI): Dr Kate Rothwell
Genetics of Endometrial Cancer: A population based study of genetic predisposition and gene-environment interactions in endometrial cancer.
Principal Investigator (PI): Dr Uschi Hofmann
SKYSCRAPER: A Phase III, Open-label, Randomised Study of Atezolizumab and Tiragolumab Compared with Durvalumab in Patients with Locally Advanced Unresectable Stage III Non-Small-Cell Lung Cancer Who have not progressed After Concurrent Platinum-based Chemo Radiation.
Principal Investigator (PI): Dr Emma Rathbone
HORIZONS:Understanding the impact of cancer diagnosis and treatment.
Principal Investigator (PI): Mrs Georgina Turner
IRAMP: A Study Exploring Research Access for People with Mesothelioma via Interviews with Patients, Carers and Health Care Professionals Who Have Experience of the Condition.
Principle Investigator (PI): Mr Simon Bolton
IMreal: A Non-Interventional, Multicenter, Multiple Cohort Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions In Patients Treated in Routine Clincial Practice.
Principal Investigator (PI):Dr Nick Brown
LI-1: Leukaemia Lymphoma Research and NCRI Working Group Pick a Winner Programme (LI1) Trial.
Principal Investigator (PI): Dr Kate Rothwell
MaPLe:Molecular profiling for lymphoma.
Principle Investigator (PI): Dr Kate Rothwell
Myeloma XII (ACCoRd trial): A phase III study to determine the role of ixazomib as an Augmented Conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT Consolidation and maintenance strategy in patients with Relapsed multiple myeloma.
Principal Investigator (PI): Dr Sylvia Feyler
Myeloma XIV (FiTNEss): Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma: A phase III trial to compare standard and frailty-adjusted induction therapy with ixazomib, lenalidomide and dexamethasone (IRD) and maintenance lenalidomide (R) to lenalidomide plus ixazomib (R+I).
Principal Investigator (PI): Dr Sylvia Feyler
NIMBLE: Nodule Immunophenotyping biomarker for lung cancer early diagnosis study.
Principal Investigator (PI): Dr Steven Thomas
PATCH: Prostate Adenocarcinoma: TransCutaneous Hormones: A Randomised Controlled Trial of Transcutaneous Oestrogen Patches Versus LHRH Agonists in Prostate Cancer.
Principal Investigator (PI): Dr Uschi Hofmann
POETIC: Trial of Perioperative Endocrine Therapy - Individualising Care.
Principal Investigator (PI): Dr Werbena Hamilton-Burke
PrecisionPanc: Advancing personalised medicine treatment strategies for pancreatic cancer.
Principal Investigator (PI): Dr Emma Rathbone
PRIMETIME: Post-operative avoidance of radiotherapy: biomarker selection of women categorised to be in a very low risk group by IHC4+C.
Principal Investigator (PI): Mr Neil Roberts
PRIMUS 001: An adaptive phase II study of FOLFOX-A (FOLFOX and nab-paclitaxel) versus AG (nab-paclitaxel and gemcitabine) in patients with metastatic pancreatic cancer, with integrated biomarker evaluation.
Principal Investigator (PI): Dr Emma Rathbone
RaNGO: Rare Neoplasms of Gynaecological Origin.
Principal Investigator (PI): Dr Deivasikamani Ramanujam
ROSCO: Response to Optimal Selection of neo-adjuvant Chemotherapy in Operable breast cancer: A randomised phase III, stratified biomarker trial of neoadjuvant 5-Fluorouracil, Epirubicin and Cyclophosphamide vs Docetaxel and Cyclophosphamide chemotherapy.
Principal Investigator (PI): Dr Deivasikamani Ramanujam
STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy.
Principal Investigator (PI): Dr Uschi Hofmann
MARECA: National study of management of breast cancer locoregional recurrence and oncological outcome.
Principal Investigator (PI): Dr Richard Frame
UKALL 2011: United Kingdom National Randomised Trial for Children and Young Adults with Acute Lymphoblastic Leukaemia and Lymphoma 2011.
Principal Investigator (PI): Dr Gill Sharpe
UNIRAD: Randomized, Double-Blind, Multicentre Phase III Trial Evaluating the Safety and Benefit of Adding Everolimus to Adjuvant Hormone Therapy in Women with Poor Prognosis, ER+ and HER2- Primary Breast Cancer Who Remain Free of Disease.
Principal Investigator (PI): Dr Jo Dent
Cardiovascular
EVAREST:The Use of Blood Biomarkers, Including Extracellular Vesicles, to Improve the Diagnostic Accuracy of Cardiac Assessment by Stress Echocardiogram.
Principal Investigator (PI): Dr Azeem Sheikh
ZODIAC: OptimiZation of Lipid Lowering Therapies Using a DSS in ACS: Implementation of a Decision Support System and its Effect On Early Optimisation of Lipid-Lowering Therapies in Patients with Acute Coronary Syndrome: A Cluster Randomised Controlled Trial.
Principal Investigator (PI): Dr Azeem Sheikh
ORION-4:A Double-Blind Randomised Placebo-Controlled Trial Assessing the Effects of Inclisiran On Clinical Outcomes Among People with Atherosclerotic Cardiovascular Disease.
Principal Investigator (PI): Dr Sabari Haridass
Gastroenterology
CLARITY IBD: Impact of Biologic Therapy on SaRs-Cov-2 Infection and Immunity.
Principal Investigator (PI): Dr Sunil Sonwalkar
M14-533: A Phase 3 Multicenter, Open-Label Extension (OLE) Study to Evaluate the Long-Term Safety and Efficacy of ABT-494 in Subjects with Ulcerative Colitis.
Principal Investigator (PI): Dr Sunil Sonwalkar
Endocrinology
IS354CS5: A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients with Severe Hypertriglyceridemia.
Principal Investigator (PI):Dr Sabari Haridass
Maternity
CHAPTER: Childbirth Acquired Perinatal Trauma Study; a Cohort Study.
Principal Investigator (PI): Dr Tina Verghese
GBS3: The Clinical and Cost-Effectiveness of Testing for Group B Streptococcus: A Cluster Randomised Trial with Economic and Acceptability Evaluations.
Principal Investigator (PI): Dr Julie Goddard
SUNNY:A Randomised Controlled Trial to Investigate the Feasibility and Acceptability of Snacktivity™ in Pregnant Women.
Principal Investigator (PI): Ms Melanie Struthers
Paediatrics
AZTEC2: Long Term Follow-Up of Azithromycin Therapy for Chronic Lung Disease of Prematurity The AZTEC 2 (Azithromycin Therapy for Chronic Lung Disease 2)
Principal Investigator (PI): Dr James Houston
Azithromycin Therapy for Chronic Lung Disease of Prematurity: A Randomised, Placebo Controlled Trial of Azithromycin for the Prevention of Chronic Lung Disease of Prematurity in Pre-Term Infants.
Principal Investigator (PI):Dr James Houston
Genetic Determinants of Kawasaki Disease: Genetic Determinants of Kawasaki Disease for Susceptibility and Outcome.
Principal Investigator (PI): Dr Khaleel-Ur Rahman
SINEPOST:SARS-CoV-2 Infection in Neonates or in Pregnancy: Outcomes at Eighteen months.
Principal Investigator (PI):Mrs Georgina Turner
CF START: The Cystic Fibrosis (CF) Anti-Staphylococcal Antibiotic Prophylaxis Trial (CF START), A Randomised Registry Trial to Assess the Safety and Efficacy of Flucloxacillin as a Long-Term Prophylaxis Agent for Infants with CF.
Principal Investigator (PI): Dr James Houston
Physiotherapy
WISE: Wrist Injury Strengthening Exercise: Progressive Resistance and Flexibility Exercises Versus Usual Care Advice for Improving Pain and Function After Distal Radius Fracture in Adults Aged 50 Years or Over: the WISE Randomised Superiority Trial.
Principal Investigator (PI): Ms Claire Paxman
Radiology
MIDI: Deep Learning for Identification of Abnormalities on Head MRI.
Principal Investigator (PI):Mrs Georgina Turner
Sexual Health
C2C: COMBINE-2 for Cabotegravir+Rilpivirine LA Regimen.
Principal Investigator (PI): Dr Emma Street
DEVA: Dequalinium Versus Usual Care Antibiotics for the Treatment of Bacterial Vaginosis.
Principal Investigator (PI): Dr Emma Street
Stroke
ENRICH-AF: Edoxaban for IntraCranial Haemorrhage Survivors with AF.
Principal Investigator (PI):Dr Syed Ahmad
OPTIMAS: Optimal Timing of Anticoagulation After Acute Ischaemic Stroke: A Randomised Controlled Trial.
Principal Investigator (PI): Dr Manohar Kini
Surgical
RECOVER TOGETHER: Improving Recovery After Bowel Cancer Surgery: Mixed-Method Feasibility Study of a Co-Produced Information Intervention.
Principal Investigator (PI): Ms Claire MacDonald
Trauma & Orthopaedics
PROFHER2: A Three-Arm Randomised Controlled Trial to Assess the Effectiveness and Cost-Effectiveness of Reverse Shoulder Arthroplasty Versus Hemiarthroplasty Versus Non-Surgical Care for Acute Three and Four-Part Fractures of the Proximal Humerus in Patients Over 65 Years of Age – Proximal Fracture of the Humerus: Evaluation by Randomisation Trial No.2.
Principal Investigator (PI):Mr Neil Pennington
SYNC01: Development of a new Patient Reported Outcome Measure (PROM) to assess patient’s emotional wellbeing and perceptions of Total Knee Replacement surgery for the treatment of knee arthritis.
Principal Investigator (PI): Dr Andreea Jimenez
